Genertec Universal Medical Group Co. Ltd. reported a stable and improving operation for the first quarter of 2025. During this period, the Group's sales increased by approximately 16.1% compared to the same period in 2024. The profit for the period also saw an increase of about 14.3% compared to the previous year, with the profit attributable to owners of the parent rising by approximately 16.7%. In the integrated healthcare business segment, the Group made significant efforts to enhance the quality and efficiency of healthcare services. This was achieved through standardized disease management, optimizing medical resource utilization, and ensuring effective treatment and service quality. The member medical institutions under the Group noted an increase in outpatient and emergency visits, demonstrating strong performance in the first quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。